March 24, 2021 -- Clover Biopharmaceuticals and Dynavax announced they have begun a phase II/III clinical trial to evaluate the efficacy of Clover's protein-based S-Trimer COVID-19 vaccine candidate.
The first participants have been given the vaccine candidate, which is adjuvanted with Dynavax's CpG 1018 plus alum. About 22,000 participants who are 18 or older are expected to be enrolled in the trial across Latin America, Asia, Europe, and Africa. The study is fully funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and will make the vaccine available through the COVAX Facility upon regulatory approval.
Clover's Trimer-Tag drug development platform, which allows the production of novel, covalently-trimerized fusion proteins, was used to develop the recombinant spike protein-based vaccine candidate.
Interim analysis of the primary endpoint expected in the middle of 2021, according to the companies.